Identification of a novel Mcl-1 protein binding motif

William J Placzek1, Mattia Sturlese, Bainan Wu

  • 1Sanford-Burnham Medical Research Institute, La Jolla, California 92037, USA.

Insights

Researchers identified novel reverse BH3 (rBH3) peptides that selectively bind to Mcl-1, a key protein in cancer therapeutic resistance. These rBH3 peptides offer potential for developing more specific Mcl-1 antagonists and discovering new apoptosis regulators.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Cancer Research

Background:

  • Mcl-1 is a primary anti-apoptotic protein in solid tumors, contributing to therapeutic resistance.
  • Understanding Mcl-1's role in apoptosis signaling is crucial for developing new cancer therapies.

Purpose of the Study:

  • To screen for peptides that bind to the Mcl-1's Bcl-2 homology 3 (BH3) binding groove.
  • To identify novel Mcl-1 antagonists and understand their binding mechanisms.

Main Methods:

  • Utilized Sabutoclax, an Mcl-1 antagonist, to screen a phage display library for binding peptides.
  • Employed NMR spectroscopy, fluorescence polarization displacement assays, and alanine scanning to characterize peptide binding.
  • Searched for proteins containing the identified reverse BH3 (rBH3) motif.

Main Results:

  • Identified canonical BH3 domain peptides and unique reverse BH3 (rBH3) peptides.
  • rBH3 peptides exhibit a reversed organization of hydrophobic and acidic residues compared to canonical BH3 sequences.
  • rBH3 peptides selectively bind to Mcl-1's BH3 binding groove over Bcl-x(L).
  • Discovered novel Mcl-1 protein partners, some linked to apoptosis regulation.

Conclusions:

  • rBH3 peptides represent a novel class of Mcl-1 binders.
  • These findings facilitate the development of specific Mcl-1 antagonists.
  • Opens avenues for identifying new Mcl-1 interacting proteins involved in apoptosis regulation.